Selected References:
- English language version of Summary of Product Characteristics for Ilumetri (tildrakizumab) Accessed: https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf.
- Haycraft K, DiRuggiero D, Rozzo S, et al. 2020. Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme. Br J Dermatol, 183: 184-186.
- Iluyma® Prescribing Information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed on August 7th, 2019.
- Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol. 2020;37(6):821-830. doi:10.5114/ada.2020.102089
- Smith C, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br. J. Dermatol., 183: 628-637.
- Yeung J, Gooderham MJ, Grewal P, et al. 2020. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. J Cutan Med Surg. 24(1_suppl):3S-14S.
